BofA DMD Expert Call Positions Sarepta Therapeutics (SRPT) Ahead of Pfizer (PFE)

BofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $180.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) after hosting an expert call with Dr. Nicholas Silvestri, a neurologist discussing gene therapies in Duchenne Muscular Dystrophy (DMD).

The analyst stated "He views ‘9001 superior than competitor PFE’s ‘926 particularly on safety and expects preference of SRPT’s ‘9001 over Pfizer's (NYSE: PFE) ‘926 at launch"
.

For an analyst ratings summary and ratings history on Sarepta Therapeutics click here. For more ratings news on Sarepta Therapeutics click here.

Shares of Sarepta Therapeutics closed at $154.05 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• SoundThinking (SSTI) PT Lowered to $8 at Cantor Fitzgerald
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery